Propofol

Lore & Background

Propofol was first synthesized in 1973 by John B. Glen, a British veterinary anesthesiologist working for Imperial Chemical Industries. It was initially formulated in Cremophor for human use, but that formulation was associated with an unacceptable number of anaphylactic events. It was eventually manufactured as a 1% emulsion in soybean oil, giving it a white milky color.

Reader's Guide

Propofol is significant as the drug used almost exclusively to induce general anesthesia, having largely replaced sodium thiopental. It is often administered as part of total intravenous anesthesia, using manually programmed or computer-controlled infusion pumps. In the intensive care unit, propofol is used to sedate patients receiving mechanical ventilation and is considered superior to lorazepam in effectiveness and overall cost, partly because benzodiazepines tend to accumulate in critically ill patients. Its use in procedural sedation, such as gastrointestinal endoscopy and pediatric MRI, results in faster recovery compared to midazolam. Propofol is also recommended for refractory status epilepticus. However, it has notable side effects, including pain on injection, low blood pressure, transient apnea, and respiratory depression. In children, side effects have been more concerning, leading to an FDA warning after reported deaths in the 1990s. Recreational use is rare but dangerous due to a steep dose-response curve, and attention to off-label use increased after the death of Michael Jackson in 2009, attributed to a mixture of propofol and benzodiazepines.

Did You Know?

• Propofol was first synthesized in 1973 by British veterinary anesthesiologist John B. Glen.
• Propofol is manufactured as a sterile injectable emulsion using soybean oil and lecithin, giving it a white milky color.
• Propofol is on the World Health Organization's List of Essential Medicines.
• Recreational use of propofol is relatively rare but has been described among medical staff, such as anesthetists.

Origins and Regulatory Path

Propofol traces its origins to 1973, when British veterinary anesthesiologist John B. Glen, working at Imperial Chemical Industries (later absorbed into AstraZeneca), first synthesized the compound. For over a decade, the molecule remained largely theoretical before it found its way into clinical practice. In 1986, it was introduced for therapeutic use as a lipid emulsion in the United Kingdom and New Zealand, marketed under the brand name Diprivan. The United States followed in October 1989 when the FDA granted approval. Today, propofol holds a place on the World Health Organization's List of Essential Medicines, a designation that underscores its global importance in anesthesia. Its trajectory from a laboratory synthesis in a British industrial setting to a cornerstone of modern surgical practice worldwide represents one of the more straightforward success stories in pharmaceutical development, particularly given how it has come to dominate the field of intravenous anesthetic induction, largely displacing the older agent sodium thiopental.

Clinical Versatility Across Settings

Propofol's clinical footprint extends far beyond the operating room. As the near-exclusive agent for inducing general anesthesia, it has largely supplanted sodium thiopental, and it serves as the backbone of total intravenous anesthesia, delivered through manually programmed or computer-controlled infusion pumps in a technique known as target controlled infusion. In intensive care units, propofol is the preferred sedative for mechanically ventilated patients who are not undergoing surgery, where it outperforms lorazepam in both effectiveness and overall cost, partly because benzodiazepines like midazolam and lorazepam tend to accumulate in critically ill patients and prolong sedation. Its rapid onset and recovery profile make it ideal for gastrointestinal endoscopy, where it yields faster recovery than midazolam, and for sedating infants and children during MRI scans, often in combination with ketamine. Multiple guidelines also recommend propofol for refractory status epilepticus, defined as seizure activity persisting beyond five minutes that requires anticonvulsant intervention. In intubated and sedated patients, it is frequently paired with fentanyl for pain relief, the two drugs being molecularly compatible in a single IV mixture.

Formulation and Manufacturing Challenges

Despite its clinical ubiquity, propofol is considered difficult to manufacture in its commercial sterile emulsified form. The drug's journey to its current formulation was not without setbacks. The initial preparation for human use employed Cremophor as a vehicle, but this original formulation was linked to an unacceptable number of anaphylactic events, prompting a complete reformulation. The solution was to manufacture propofol as a one-percent emulsion in soybean oil, with lecithin serving as an emulsifying agent. This combination is what gives the drug its characteristic white, milky appearance. Sterile emulsions are inherently complex formulations whose stability depends on the delicate interplay of numerous factors, including micelle size and distribution. The result is a product that must be administered intravenously—either as a bolus, a continuous infusion, or a combination of the two—through a peripheral IV or central line. The manufacturing challenges underscore why propofol, despite being relatively inexpensive compared to similar medications, cannot be casually replicated outside of regulated pharmaceutical production.

Controversies and Off-Label Use

Propofol's potency and the steepness of its dose-response curve have made it a subject of significant controversy outside the controlled clinical setting. Recreational self-administration, while relatively rare, is exceedingly dangerous, and deaths continue to be reported. The drug's short-term effects—mild euphoria, hallucinations, and disinhibition—have drawn the attention of medical staff, particularly anesthetists on rotations with short rest periods, who reportedly use it to achieve a well-rested feeling; long-term use has been linked to addiction. Public awareness of the drug's lethality surged in August 2009, when a coroner's report determined that musician Michael Jackson died on June 25, 2009, from a mixture of propofol and the benzodiazepines lorazepam, midazolam, and diazepam. A court-unsealed affidavit revealed that his physician, Conrad Murray, had administered twenty-five milligrams of propofol diluted with lidocaine shortly before Jackson's death. Propofol has also been considered for capital punishment protocols, though no execution has used it, largely because European manufacturers and governments have banned its export for that purpose. In Canada, a lethal dose of propofol is employed in medical assistance in dying to induce deep coma and rapid death, always accompanied by rocuronium as a paralytic.